Oct 30,2024 TOP STORY

Beta Bionics Announces Launch of the iLet Bionic Pancreas with Abbott’s FreeStyle Libre 3 Plus sensor

Beta Bionics has launched its iLet Bionic Pancreas integrated with Abbott's FreeStyle Libre 3 Plus sensor, providing fully autonomous insulin delivery for people with diabetes. The iLet calculates insulin doses using minute-by-minute glucose data from the sensor, removing the need for carb counting or manual insulin corrections. Beta Bionics also released the Bionic Circle App, allowing up to 10 family members or friends to remotely monitor users’ glucose levels and insulin doses. This integration offers a new approach to diabetes management with convenient access through pharmacies and a pay-as-you-go model.

PRODUCT

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 30,2024 TOP STORY

ABBOTT'S FREESTYLE LIBRE® 2 AND 3: FIRST CONTINUOUS GLUCOSE MONITORING SYSTEMS APPROVED FOR USE DURING MEDICAL IMAGING

Abbott announced that its FreeStyle Libre 2 and 3 continuous glucose monitoring (CGM) systems have received FDA clearance for use during common imaging procedures like X-rays, CT scans, and MRIs, making them the first CGM systems approved for this use. Previously, patients had to remove and discard their CGM sensors before imaging, causing data gaps and added costs. The updated clearance allows patients to maintain continuous glucose monitoring throughout these procedures, supporting uninterrupted diabetes management and improving convenience and affordability. Abbott’s rigorous testing ensured sensor efficacy post-imaging, reflecting its dedication to accessible diabetes care innovations.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 12,2024

Blood Glucose Monitoring Devices Market size is set to grow by USD 8.70 billion from 2024-2028, Rising global burden of diabetes to boost the market growth, Technavio

The global blood glucose monitoring devices market is projected to grow by $8.7 billion from 2024 to 2028 at a CAGR of 9.45%, driven by the increasing prevalence of diabetes worldwide and a shift towards convenient, smartwatch-based monitoring applications. This trend reflects a preference for wearable, real-time glucose management tools that integrate continuous glucose monitoring (CGM) directly into everyday devices, enhancing ease of use and accessibility for users. Leading companies such as Abbott, Medtronic, and Dexcom are expanding offerings in both hospital and home-care segments, focusing on innovations in glucose meters, insulin pumps, and CGM systems.

#bgm

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Sep 05,2024

Utilizing Continuous Glucose Monitoring for Early Detection of Gestational Diabetes Mellitus and Pregnancy Outcomes in an Asian Population

A study of 103 overweight or obese Asian women in early pregnancy found that continuous glucose monitoring (CGM) may effectively predict gestational diabetes mellitus (GDM) and adverse pregnancy outcomes, such as primary cesarean delivery and larger-than-average newborns. CGM-derived metrics outperformed traditional risk models in predicting GDM, suggesting that CGM could be valuable in early pregnancy screenings to improve outcomes for high-risk pregnancies.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 23,2024

Netherlands Diabetes Device Market Forecast Report and Company Analysis 2024-2032 Featuring Dexcom, Medtronic, Roche, Abbott Laboratories, Eli Lilly, Terumo, & BD

The Netherlands' diabetes device market is projected to grow from $343.4 million in 2023 to $641.7 million by 2032, driven by an aging population, increased diabetes prevalence, and rising demand for remote monitoring solutions. With technological advances and government health initiatives, devices like insulin delivery systems and continuous glucose monitors are increasingly vital for disease management. Remote monitoring, facilitated by continuous glucose monitors and health apps, allows for proactive diabetes care and reduces the need for in-person consultations. Key players in this market include Dexcom, Medtronic, Roche, and Abbott Laboratories.

#cgm

#bgm

#insulin pump

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Oct 23,2024

Japan Diabetes Device Market Forecast Report and Company Analysis 2024-2032 Featuring Abbott Laboratories, Roche, Medtronic, Novo Nordisk, Terumo, Eli Lilly, BD, and Dexcom

The Japan Diabetes Device Market is projected to grow significantly, reaching $2.8 billion by 2032, driven by a 7.49% annual growth rate. Key factors include government-supported health initiatives by the Ministry of Health, Labour and Welfare (MHLW), which emphasize early diabetes detection and subsidize devices like insulin pumps and continuous glucose monitors (CGMs). National awareness campaigns also increase understanding of diabetes prevention, encouraging broader adoption of advanced monitoring technologies. Companies such as Abbott, Roche, Medtronic, and Dexcom are expected to play major roles in this expanding market.

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Aug 30,2024

Accuracy of Continuous Glucose Monitoring in Hemodialysis Patients With Diabetes

A recent study published in Diabetes Care investigates the accuracy of continuous glucose monitoring (CGM) compared to traditional blood glucose measurements for hemodialysis patients with diabetes. The study, conducted on 31 patients using the Dexcom G6 CGM, found a moderate correlation between CGM and blood glucose readings, with a mean difference of around +15 mg/dL. Although accuracy was lower during hemodialysis, error grids indicated that nearly all CGM readings were within clinically acceptable ranges. The findings highlight the potential for CGM use in this patient group, though further research is needed to confirm its benefits.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 15,2024

The $2.62bn Diabetes Devices Industry Landscape in Germany, 2024-2032 - Personalized Medicine and AI Drive Growth in the Advanced Diabetes Devices Market

The Germany Diabetes Device market is projected to grow from US$ 1.39 billion in 2023 to US$ 2.62 billion by 2032, with a CAGR of 7.3%. Key players like Abbott, Roche, and Medtronic are leading innovation in insulin pumps, continuous glucose monitors (CGMs), and blood glucose meters. The market's rapid growth is driven by rising diabetes prevalence, technological advancements, and the German government's focus on preventative care and chronic disease management. Digital health solutions, such as telemedicine and AI-driven devices, are playing an increasingly significant role in improving patient engagement and outcomes.

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 10,2024

Mercy Places First Commercial Eversense 365: The World’s First and Only 365-Day Continuous Glucose Monitor

Senseonics Holdings, Inc. announced that its Eversense 365 continuous glucose monitoring (iCGM) system has been approved in the U.S. for adults with Type 1 and Type 2 diabetes. This next-generation system, now commercially launched by Ascensia Diabetes Care, allows for one year of continuous glucose monitoring with minimal interruptions, requiring only one calibration per week and no additional sensor replacements. The first patient to receive the Eversense 365 system is part of a collaboration with Mercy, a major healthcare provider, which expects about 30,000 of its patients could benefit from this technology. Senseonics and Mercy expect this significant breakthrough in diabetes technology and management to improve glycemic control for patients, reduce distress associated with managing diabetes and lower overall healthcare costs for providers and payers.

COLLABORATION PARTNERSHIP

#cgm

#institution

View Analyst & Ambassador Comments
Go to original news
Oct 07,2024

Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the successful completion of its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM) technology. The study assessed the analytical performance of CGM technology enhancements implemented by Trinity Biotech since acquiring the technology from Waveform Technologies in January 2024.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM